Ocrelizumab as a breakthrogh in multiple sclerosis treatment

• DOI: 10.12775/jehs.2021.11.05.005
• Publication Date: 2021-06-08T07:01:27Z
• Authors: Marcin Zaniuk; Marta Kozłowska; Adrianna Gorecka; Magdalena Zawiślak; Patryk Zimnicki
• Keywords: Ocrelizumab

Multiple sclerosis is the most commonly occurring inflammatory disease of nervous system. It estimated that over 2 million people suffer from this disease. Currently SM untreatable, one can only try to stop progression or reduce severity symptoms. There have been numerous studies on effectiveness other monoclonal antibodies in treatment multiple sclerosis. A drug offers a chance for breakthrough ocrelizumab. antibody directed against B lymphocytes expressing CD20 antigen. Results studie confirm efficacy ocrelizumab inhibiting ongoing nerve fiber degeneration and reducing inflammation associated with it, as well near complete depletion CD20+ partial T lymphocytes. They also suggest safe effective sclerosis.Studies conducted therapeutic show its effect superior compared some current drugs. Ocrelizumab has similar safety profile currently used interferon β-1a. An important feature primary progressive form MS, where significant drugs not seen date.